# Comparative Effectiveness of AKYNZEO® and Standard of Care (Including EMEND®) for the Prevention of Nausea and Vomiting (CINV) in Cancer Patients

> **NCT03831633** · PHASE4 · UNKNOWN · sponsor: **VIFORFRANCE** · enrollment: 426 (estimated)

## Conditions studied

- Oncology

## Interventions

- **DRUG:** Akynzeo
- **DRUG:** Standard of Care

## Key facts

- **NCT ID:** NCT03831633
- **Lead sponsor:** VIFORFRANCE
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-09-19
- **Primary completion:** 2019-07-31
- **Final completion:** 2019-07-31
- **Target enrollment:** 426 (ESTIMATED)
- **Last updated:** 2019-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03831633

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03831633, "Comparative Effectiveness of AKYNZEO® and Standard of Care (Including EMEND®) for the Prevention of Nausea and Vomiting (CINV) in Cancer Patients". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03831633. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*